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meeting people
tv; also, MPs tried the “PKU Diet-for-a-Day” challenge, which 
they publicised on social media. The diet challenge, restricting 
the diet to ≤10g of protein in one whole day, happened on 
International PKU Awareness Day - on 28 June 2018 - and was 
the subject MPs were most tweeting about on that day. 
What Was your Most reWardInG achIeVeMent?
I was pleased to appear on the BBC news channel to explain 
PKU and the way that the pharmacological treatment 
sapropterin (also called BH4, tetrahydrobiopterin, trade name 
Kuvan®) could change lives for responders who have PKU. 
Tetrahydrobiopterin is an enzyme chaperone for the defective 
enzyme in PKU – PAH - and thus it can remove the significant 
burden of dietary treatment in responders. The BBC news item 
was following the report of a successful high court case for a 
small boy with PKU who is autistic and is now allowed to have 
BH4 funded by NHS England. 
A recent team effort that NSPKU volunteers and I undertook 
has been the analysis of the biggest PKU experiences survey 
done so far in the world; the survey was completed online by 
people living with PKU in the UK. We have now published 
the survey results in two papers in Molecular Genetics and 
Metabolism Reports. The widespread nature of difficulties 
was still a surprise to me and the experiences of women was 
shocking. Women felt frightened by messages about the dangers 
of unplanned pregnancies (phenylalanine is teratogenic); the 
burden of pregnancy is high, and the difficulty of self-care and 
PKU treatment management in combination with motherhood 
is a significant challenge. 
can you dIscuss the eVents WhIch you orGanIse and hoW do you 
secure fundInG? hoW Is the assocIatIon InVolVed In research?
The NSPKU has an annual weekend conference for families, 
day-long educational events, health care professional 
meetings and training sessions. We rely on our community 
for fundraising: people running ultra-marathons, holding 
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Phenylketonuria (PKU) is an autosomal recessive condition. 
The amino acid phenylalanine is usually metabolized to tyrosine 
by the enzyme phenylalanine hydroxylase [PAH] also requiring 
a cofactor named tetrahydrobiopterin. In phenylketonuria, 
phenylalanine is not metabolized to tyrosine. Phenylalanine is 
an essential aromatic amino acid. High phenylalanine levels in 
patients with PKU can result in neurotoxicity. The mainstay of 
treatment is protein restriction in the diet.
hoW dId you becoMe InVolVed WIth the nsPKu? 
I work as a dietitian in the NHS, supporting adults with PKU 
and have done this since 2009; I knew the NSPKU provided 
other services and support. I had already spoken at the society’s 
conference and stood in for the society dietitian at another 
event, so when the post became vacant I was pleased to have this 
great opportunity.
can you tell Me More about the orIGIns of the socIety? 
The NSPKU was founded in 1973 by Brian and Sylvia Smith 
who put an announcement out on national radio to appeal for 
interest in meeting other families affected by the disorder – 
they also wrote to dietitians and other families that they had 
addresses for. There was a preliminary meeting in a community 
centre in November in 1973 and then the first General Meeting 
in April 1974 in Blackpool. In 1975 a Medical Advisory Panel 
had been added and in 1983 the society employed its first 
dietitian, and had an internet presence by 1996.
do you belIeVe the aWareness of PhenylKetonurIa 
has chanGed alonG the years? 
The families who live with PKU have always been instrumental 
in calmly explaining what PKU is to others who need to know. 
In the UK, recently families and people living with PKU have 
surpassed themselves by writing to MPs and alerting them to 
the life challenges this disorder brings to those affected. These 
MPs have held debates in parliament – filmed on parliamentlive.
Suzanne Forddr Michelle Muscat interviews suzanne ford, the Society Dietitian at The National Society for Phenylketonuria [NSPKU], in the UK.
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have discontinued diet; we should be supporting them to re-
access treatment. However, we don’t necessarily know where 
these “lost to follow-up” patients are in the UK, it’s possible they 
are in the community experiencing adverse clinical outcomes of 
untreated PKU. There are many challenges ahead.
More information may be found on the website: 
www.nspku.org/ 
I WIll read the synaPse Journal because…
This is the first time I encountered this publication… 
having gone through it, I must say that it’s a concise, 
relevant and informative read!
NSPKU takes food for Phenylalanine analysis each year - Avocado after 
Phenylalanine Analysis
book sales and fundraising “extravaganzas” as well as regular 
donations from funerals, bake sales, prize raffles, collection tubs 
and many other efforts, events and endeavours.
Each year the NPSKU sponsors research – we have a grant 
fund offering two grants up to £10,000 annually, which are 
awarded following assessment by our Medical Advisory Panel. 
can you exPlaIn further about PossIble MedIcal adVanceMents 
on the horIzon you are Personally excIted about? 
The drug treatment for PKU which is potentially nearest to 
being available in England is the above-mentioned BH4 – 
however, we estimate only 30% of people with PKU in the UK 
will respond to BH4. Pegvaliase (currently available in the US), is 
an enzyme substitution therapy for PKU which is injectable, and 
is only suitable for adults due to immunology effects. 
The most exciting treatment in my opinion is a genetically 
engineered probiotic treatment which has successfully been 
through mice trials. The bacteria Lactobacillus reuteri was given 
a phenylalanine lyase gene from another bacteria, Anabaena 
variabilis. PKU mice had reduced blood phenylalanine levels 
after 3-4 days of treatment with the genetically modified 
probiotic. This seems like it would be a potentially effective 
treatment. The enzyme Phenylalanine lyase does the same job as 
the PAH which is impaired in PKU.
What do you enVIsaGe In the future for the nsPKu?
The key achievement for us will be when everyone living with 
PKU in the UK is receiving PKU treatment to the standards 
outlined in the European Guidelines for Diagnosis and 
Management of PKU (published in brief in The Lancet Diabetes 
and Endocrinology and also in full in the Orphanet Journal of 
Rare Diseases, both in 2017). One of the many recommendations 
includes metabolic specialist input for people with PKU who 
have, in the past, been discharged from metabolic clinics, or 
In very challenging winter conditions, Andrew Tasker and friends ascend Ben Nevis, Britain's highest peak, raising £3.5k for NSPKU, Andrew has a 4 year old son with PKU
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